– a superior pancreata preservation
solution for subsequent islet
cell isolation for the treatment
of Type 1 Diabetes.
LET Protect™ – a superior pancreata preservation solution for subsequent islet cell isolation for the
treatment of Type 1 Diabetes.
One of the most challenging issues in organ transplantation is the limited time available between
donation of the organ and implantation in the receiving patient. A lot of costly infrastructure is needed
to allow all steps to be organized in a coordinated fashion. Efficient time management is crucial to
preserve the vital integrity of donated organs.
The use of novel solvents that allow the supply of oxygen to the entire tissue to prevent cold ischemia
damage is a key component. The traditionally used oxygen carrier perfluorodecalin (PFD) only has a
moderate effect on oxygen supply to tissue parts. Novaliq’s new admixture of perfluorohexyloctane and
polydimethylsiloxane has shown to be superior to PFD in recently published studies by Brandhorst et
al (2010) for preservation of pancreas and is now CE-approved and commercially available.
I-LET PROTECT ®
– a superior pancreata preservation
solution for subsequent islet cell isolation
for the treatment of Type 1 Diabetes.
• Human pancreas storage is significantly improved using I-LET PROTECT ®
• Enhanced oxygen penetration into pancreatic tissue
• Increased quality of isolated islets
• First oxygen carrierwith a pancreas-specific density of 1,13 g/cm3
“A new oxygen carrier for improved long-term
storage of human pancreata before islet isolation”.
Brandhorst H, Asif S, Andersson K, Theisinger B, Andersson
HH, Felldin M, Foss A, Salmela K, Tibell A, Tufveson G,
Korsgren O, Brandhorst D. Transplantation. 2010 Jan
27;89(2):155-60
“Perfluorohexyloctane improves long-term
storage of rat pancreata for subsequent islet
isolation”.
Brandhorst H, Theisinger B, Yamaya H, Henriksnäs J,
Carlsson PO, Korsgren O, Brandhorst D. Transpl Int.
2009 Oct;22(10):1017-22. Epub 2009 Jul 10.
Novaliq GmbH is a drug delivery company located in the
Heidelberg Technology Park, Germany.
They develop innovative pharmaceutical formulations based on semifluorinated alkanes (SFAs).
Their patented SFAs can be used in various routes of administration for the transport of drugs or oxygen
for therapeutic purposes. Novaliq currently develops novel ophthalmic and dermatological products as
well as solutions for organ preservation, based on the unique physicochemical properties of SFA.
Their first product on the market is I-let Protect™ an organ preservation liquid based on SFA.
Besides the development of its own products and licensing them to pharmaceutical distributors, Novaliq
is offering its SFA technology as a delivery platform for external co-development cooperations.
Novaliq employs an innovative carrier system for topical drug delivery in particular for poorly soluble
drugs. This liquid carrier system is based on a unique class of partially fluorinated substances, semifluorinated
alkanes. They have unique properties covered by a strong patent portfolio that can be used for a variety
of administration routes and purposes. Routes of administration include among others ocular, dermal,
buccal and nasal. The unique properties include solubilization of poorly soluble drugs, serving as an
oxygen carrier and modulating pharmacokinetic behavior of the whole system.
Novaliq's strategy is to valorize its assets by
(a) developing poorly met medical need products using the unique features of their SFA platform
(b) out-licensing their developed clinical stage and market-ready products to suitable distribution partners,
and
Novaliq GmbH
Im Neuenheimer Feld 515
D-69120 Heidelberg
Fon: +49 (0) 6221/5 02 59-0
Fax: +49 (0) 6221/5 02 59-21
Email: info[at]novaliq.de
12089 bitteragentur.de
(c) offering their delivery platform for improved delivery of drug compounds brought by their
partners for co-development.